BridgeBio have substantially advanced its development of a new treatment for cardiac amyloidosis, leveraging the compound. Early patient data suggests potential outcomes for patients suffering from a severe disease. https://attruby818143.blogolenta.com/39191479/bridgebio-advances-cardiac-amyloidosis-therapy-through-attruby